Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum

Journal of Clinical Microbiology

Volumn 37, Issue 6, 1999, Pages 1676-1682

  Woods, Gail L ^a   Bergmann, John S ^a   Witebsky, Frank G ^b   Fahle, Gary A ^b   Wanger, Audrey ^c   Boulet, Betty ^c   Plaunt, Marianne ^d   Brown, Barbara A ^e   Wallace Jr , Richard J ^e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Statprobe   (United States)

^e UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; IMIPENEM; SULFAMETHOXAZOLE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; UNCULTURED ACTINOMYCETE;

EID: 0032930591     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.6.1676-1682.1999     Document Type: Article

References (24)

1. Band, J. D., J. I. Ward, D. W. Fraser, N. J. Peterson, V. A. Silcox, R. C. Good, P. R. Ostroy, and J. Kennedy. 1982. Peritonitis due to a Mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis. J. Infect. Dis. 145:9-17.
2. Biehle, J. R., S. J. Cavalieri, M. A. Saubolle, and L. J. Getsinger. 1995. Evaluation of Etest for susceptibility testing of rapidly growing mycobacteria. J. Clin. Microbiol. 33:1760-1764.
3. Brown, B. A., J. M. Swenson, and R. J. Wallace, Jr. 1994. Broth microdilution MIC test for rapidly growing mycobacteria, p. 5.11.1. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
4. Brown, B. A., R. J. Wallace, Jr., G. O. Onyi, V. DeRosas, and R. J. Wallace III. 1992 Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob. Agents Chemother. 36:180-184.
5. Dalovisio, J. R., G. A. Pankey, R. J. Wallace, Jr., and D. B. Jones. 1981. Clinical usefulness of amikacin and doxycycline in the treatment of human infection of Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis. 3:1068-1074.
6. Griffith, D. E., W. M. Girard, and R. J. Wallace, Jr. 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am. Rev. Respir. Dis. 147:1271-1278.
7. Ingram, C. W., D. C. Tanner, D. T. Durack, G. W. Kernodle, Jr., and G. R. Corey. 1993. Disseminated infection with rapidly growing mycobacteria. Clin. Infect. Dis. 16:463-71.
8. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved Standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. 8a.National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing; eighth informational supplement. M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Bottger, and R. J. Wallace, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581.
11. Sanders, C. V., R. N. Greenberg, and R. L. Marier. 1985. Cefamandole and cefoxitin. Ann. Intern. Med. 103:70-78.
12. Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:186-192.
13. Swenson, J. M., R. J. Wallace, Jr., V. A. Silcox, and C. Thornsberry. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28:807-811.
14. Wallace, R. J., Jr., G. Bedsole, G. Sumter, C. V. Sanders, L. C. Steele, B. A. Brown, J. Smith, and D. R. Graham. 1990. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 34:65-70.
15. Wallace, R. J., Jr., B. A. Brown, and G. O. Onyi. 1991. Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicilin-clavulanic acid. Antimicrob. Agents Chemother. 35:773-775.
16. Wallace, R. J., Jr., B. A. Brown, and G. O. Onyi. 1992. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166:405-412.
17. Wallace, R. J., Jr., J. L. Cook, J. Glassroth, D. E. Griffith, K. N. Olivier, and F. Gordin. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am. J. Resp. Crit. Care Med. 156:S1-S25.
18. Wallace, R. J., Jr., J. R. Dalovisio, and G. A. Pankey. 1979. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. Antimicrob. Agents Chemother. 16:611-614.
19. Wallace, R. J., Jr., A. Meier, B. A. Brown, Y. Zhang, P. Sander, G. O. Onyi, and E. C. Bottger. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
20. Wallace, R. J., Jr, V. A. Silcox, M. Tsukamura, B. A. Brown, J. O. Kilburn, W. R. Butler, and G. Onyi. 1993. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J. Clin. Microbiol. 31:3231-3239.
21. Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, and M. G. Bullen. 1985. Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei based on in vitro susceptibilities. J. Infect. Dis. 152:500-514.
22. 20a.Wallace, R. J., Jr. Unpublished data.
23. Williams, L., C. Cook, B. Metchock, and J. Ridderhof. 1998. Drug susceptibility testing of non-tuberculous mycobacteria (NTM) among laboratories participating in the CDCs M. tuberculosis (M.tb)/NTM drug susceptibility performance evaluation program, abstr. D-91, p. 154. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Wilson, R. W., V. A. Steingrube, E. C. Bottger, B. Springer, B. A. Brown, K. C. Jost, Jr., Y. Zhang, G. Onyi, D. R. Nash, and R. J. Wallace, Jr. 1998. Recognition of a new taxon within the Mycobacterium abscessus-Mycobacterium chelonae complex and proposal of Mycobacterium immunogen sp. nov., abstr. C-310, p. 182. In Program and abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.